FDA Approves New Indication for Drug Containing an Active Ingredient Derived from Cannabis to Treat Seizures in Rare Genetic Disease

— Today, the U.S. Food and Drug Administration approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older. Epidiolex was previously approved for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome (LGS) andContinue reading “FDA Approves New Indication for Drug Containing an Active Ingredient Derived from Cannabis to Treat Seizures in Rare Genetic Disease”

Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

— Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food & Drug Administration (“U.S. FDA”) has approved the Company to proceed with a randomized, double-blind, placebo-controlled confirmatory PhaseContinue reading “Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19”

Tetra Bio-Pharma Receives Conditional Approval to Graduate to the TSX

Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSXV:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce it has received conditional approval from the Toronto Stock Exchange (the “TSX”) to graduate from the TSX Venture Exchange (“TSX-V”) and list its common shares (“Shares”) and its warrants (“Warrants”) on the TSX, subjectContinue reading “Tetra Bio-Pharma Receives Conditional Approval to Graduate to the TSX”

Naturally Splendid Provides Clinical Trial Application Update

Naturally Splendid Enterprises Ltd.  (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) provides the following update in regards to the Phase 2 Clinical Trial Application with Health Canada for a potential COVID-19 treatment. As an update to the Clinical Trial Application (CTA) process with Health Canada: A CTA was approved for submission to Health Canada on May 17, 2020. The HealthContinue reading “Naturally Splendid Provides Clinical Trial Application Update”

Charlotte’s Web Steps up to Support Research to Address FDA’s Request for More Scientific Data

ValidCare to Conduct Industry Leading Study on CBD and Human Health BOULDER, Colo., June 9, 2020 /PRNewswire/ – (TSX: CWEB) (OTCQX: CWBHF) Charlotte’s Web Holdings, Inc. (“Charlotte’s Web” or the “Company”), the company behind the world’s most trusted hemp extract™ and the CBD industry market leader, announced its sponsorship, with six other CBD brands, of ValidCare’s scientific study, toContinue reading “Charlotte’s Web Steps up to Support Research to Address FDA’s Request for More Scientific Data”